Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

被引：0
|
作者：
Michael Willis
Andreas Nilsson
Klas Kellerborg
Philip Ball
Rupert Roe
Shana Traina
Rebecca Beale
Isabelle Newell
机构：
[1] The Swedish Institute for Health Economics,
[2] Mundibiopharma Limited,undefined
[3] Napp Pharmaceuticals Limited,undefined
[4] Janssen Global Services,undefined
[5] LLC,undefined
[6] Costello Medical Consulting Limited,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Albuminuria; Canagliflozin; Chronic kidney disease (CKD); Cost-effectiveness; CREDENCE; Diabetes; Diabetic kidney disease (DKD); Diabetic nephropathy; Dialysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：313 / 328
页数：15
相关论文
共 50 条
  • [21] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [22] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [23] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [24] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [25] Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
    Reifsnider, Odette S.
    Kansal, Anuraag R.
    Gandhi, Pranav K.
    Cragin, Lael
    Brand, Sarah B.
    Pfarr, Egon
    Fahrbach, Kyle
    Ustyugova, Anastasia
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [26] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [27] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [28] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (T2DM) FAILING TO ACHIEVE GLYCAEMIC CONTROL ON METFORMIN MONOTHERAPY IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
  • [29] Simultaneous Pancreas and Kidney Transplant (SPK) - The New Standard of Care for Uremic Patients with Type 2 Diabetes Mellitus (T2DM).
    Gruessner, A.
    Laftavi, M.
    Whittaker, V.
    Acun, Z.
    Pankowycz, O.
    Gruessner, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 684 - 685
  • [30] Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States
    Zheng, Cailin
    Wu, Jinneng
    Li, Na
    Wei, Xiaoxia
    Huang, Zhixiong
    Chen, Lingbin
    Chen, Zhou
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 165 - 173
12345